Evidence map›Paper›PMID 40501445›Full record

ArticleHuman brain mapping2025

Single-Subject Network Analysis of FDOPA PET in Parkinson's Disease and Psychosis Spectrum.

Mario Severino, Julia J Schubert, Giovanna Nordio, Alessio Giacomel, Rubaida Easmin, Nick P Lao-Kaim, Pierluigi Selvaggi, Zhilei Xu, Joana B Pereira, Sameer Jauhar and 5 more

Abstract read
In one paragraph

Article in Human brain mapping, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Radiomic Analysis of Striatal [Molecular imaging and biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mario SeverinoDepartment of Information Engineering, University of Padua, Padova, Italy.ORCID 0009-0008-8361-6228
Julia J SchubertDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID 0000-0001-6102-7272
Giovanna NordioDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Alessio GiacomelDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Rubaida EasminDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Nick P Lao-KaimCentre for Neurodegeneration and Neuroinflammation, Division of Brain Sciences, Imperial College London, London, UK.
Pierluigi SelvaggiDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Zhilei XuDivision of Neuro, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Joana B PereiraDivision of Neuro, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Sameer JauharDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Paola PicciniCentre for Neurodegeneration and Neuroinflammation, Division of Brain Sciences, Imperial College London, London, UK.
Oliver HowesDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Federico TurkheimerDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Mattia VeroneseDepartment of Information Engineering, University of Padua, Padova, Italy.
FDOPA PET Imaging Working Group Consortium

Funding

Wellcome Trust
6 · The paper itself

Abstract

Greater understanding of individual biological differences is essential for developing more targeted treatment approaches to complex brain disorders. Traditional analysis methods in molecular imaging studies have primarily focused on quantifying tracer binding in specific brain regions, often neglecting inter-regional functional relationships. In this study, we propose a statistical framework that combines molecular imaging data with perturbation covariance analysis to construct single-subject networks and investigate individual patterns of molecular alterations. This framework was tested on [18F]-DOPA PET imaging as a marker of the brain dopamine system in patients with Parkinson's Disease (PD) and schizophrenia to evaluate its ability to classify patients and characterize their disease severity. Our results show that single-subject networks effectively capture molecular alterations, differentiate individuals with heterogeneous conditions, and account for within-group variability. Moreover, the approach successfully distinguishes between preclinical and clinical stages of psychosis and identifies the corresponding molecular connectivity changes in response to antipsychotic medications. Mapping molecular imaging networks presents a new and powerful method for characterizing individualized disease trajectories as well as for evaluating treatment effectiveness in future research.

Indexed as

BrainDihydroxyphenylalanineParkinson DiseasePositron-Emission TomographyPsychotic DisordersSchizophreniaAgedFemaleHumansMaleMiddle AgedRadiopharmaceuticalsDihydroxyphenylalaninefluorodopa F 18RadiopharmaceuticalsFDOPAmolecular connectivitynetwork analysisParkinson's diseasePETschizophrenia

Identifiers

PMID40501445
PMCPMC12159690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.